{"prompt": "['Rituxan Hycela Package Insert 2017. Available at:', 'ttps://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761064s000lbl.pdf', 'Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for', 'operable HER2-positive breast cancer. N Engl J Med 2005;353:1673- 84.', 'Rosengren S, Dychter SS, Printz MA et al. Clinical Immunogenicity of rHuPH20, a', 'Hyaluronidase Enabling Subcutaneous Drug Administration. AAPS J. 2015 Sep; 17(5):', '1144-1156.', 'Rummel M, Kim TM, Aversa F et al. Preference for subcutaneous or intravenous', 'administration of rituximab among patients with untreated CD20+ diffuse large B-cell', 'lymphoma or follicular lymphoma: results from a prospective, randomized, open-label,', 'crossover study (PrefMab). Ann Oncol. 2017 Apr ;28(4):836-842.', 'Runowicz CD, Leach CR, Henry NL et al. American Cancer Society/American Society of', 'Clinical Oncology Breast Cancer Survivorship Care Guideline. J Clin Oncol 2016 Feb', '20;34(6):611-35.', 'Slamon DJ, Clark GM, Wong SG et al. Human breast cancer: correlation of relapse and', 'survival with amplification of the HER-2/neu oncogene. Science. 1987 Jan', '9;235(4785):177-82', 'Slamon D, Eiermann W, Robert N et al. Adjuvant trastuzumab in HER2-positive breast', 'cancer. N Engl J Med. 2011 Oct 6;365(14):1273-83', 'Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal', 'antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl', 'J Med 2001;344:783-792.', 'Sliwkowski MX, Lofgren JA, Lewis GD et al. Non clinical studies addressing the mechanism', 'of action of trastuzumab (Herceptin). Semin Oncol 1999;26(Suppl 12):60-70.', 'Smith I, Procter M, Gelber RD et al. 2-year follow-up of trastuzumab after adjuvant', 'chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet.', '2007 Jan 6;369(9555):29-36.', 'Swain SM, Kim SB, Cortes J et al. Pertuzumab, trastuzumab, and docetaxel for HER2-', 'positive metastatic breast cancer (CLEOPATRA study): overall survival results from', 'a', 'randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 2013; 14:', '461-471.', 'von Minckwitz G, Procter M, de Azambuja E et al. Adjuvant Pertuzumab and Trastuzumab in', 'Early HER2-Positive Breast Cancer. N Engl J Med. 2017 Jul 13;377(2):122-131', 'Vu T, Claret FX. Trastuzumab: updated mechanisms of action and resistance in breast', 'cancer. Front Oncol. 2012 Jun 18;2:62.', 'SC Fixed-Dose Combination of Pertuzumab and Trastuzumab - F. Hoffmann-La Roche Ltd', '94 / Protocol MO40628, Version 12']['Appendix 1', 'Schedule of Activities', 'End of', 'Treatment Continuation', 'Follow-up', 'Screening', 'Baseline', 'Treatment Cross-over Period', 'Treatment', 'Period [c]', 'Period [a]', 'Visit [b]', '15', '11', '1', '2', '3', '4', '5', '6', '7', '(or last', 'Study Cycle', '[d]', 'treatment', 'cycle) [e]', '28 days', 'Day', '-28 to -1', '-7 to-1', '1', '1', '1', '1', '1', '1', '1', '1', '1', 'from last', 'study dose', 'Informed consent [f]', 'X', 'Medical history and', 'X', 'demographics', 'Collection of pathology', 'x', 'reports [g]', 'Complete physical', 'X', 'x', 'examination [h, i]', '[i]', 'Limited physical', 'X', 'X', 'X', 'X', 'examination [h, i]', 'Vital signs [j]', 'X', 'X', 'ECOG Performance Status', 'X', 'X', 'X', 'X', '[h]', 'Weight [h, k]', 'X', 'X', 'X', 'Height', 'X', 'SC Fixed-Dose Combination of Pertuzumab and Trastuzumab - F. Hoffmann-La Roche Ltd', '95 / Protocol MO40628, Version 12']\n\n###\n\n", "completion": "END"}